Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Milei Threatens Falkland Oil Firms With Sanctions 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Anthropic IPO Marketing Expected to Start in Mid-October 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Add as a preferred source on Google
SAN FRANCISCO, March 01, 2018 -- Syapse, a leading precision medicine company, announced today that Frank Williams, the co-founder and CEO of Evolent Health, has joined the company’s board of directors.
Williams, a healthcare industry veteran and former executive chairman and CEO of The Advisory Board Company, brings deep expertise in helping health systems evolve to a value-based care model, focused on improving clinical outcomes and financial results. He started Evolent Health in 2011 to change the way healthcare is delivered in the U.S. by enabling health systems to gain the operational scale, financial partnerships, and clinical capabilities they need to deliver better patient outcomes at lower cost.
“To truly make precision medicine a reality for every patient, we must focus on giving oncologists the data they need to make targeted treatment decisions,” Williams said. “Syapse is on a mission to do just that, and I’m thrilled to bring my expertise working with large community health systems to the table to advance this effort. I look forward to working together to bring better cancer care to more patients.”
Williams will provide strategic advice to Syapse during a time of rapid growth for the company. Syapse raised $30 million in Series D financing in late 2017, expanded to Asia earlier this year, and recently announced new partnerships with Roche and Medidata to advance precision medicine for health systems.
“Frank’s experience helping health systems evolve to a new model of care and his philosophy of serving as a trusted partner to them is perfectly aligned with Syapse’s mission,” said Ken Tarkoff, CEO of Syapse. “I am honored to welcome Frank to the Syapse board, and I know his insights and expertise will be crucial as we expand our partnerships across the industry and advance precision medicine for health systems.”
About Syapse
Syapse is on a mission to deliver the best care for every cancer patient through precision medicine. Our software platform, data sharing network, and industry partnerships enable healthcare providers to bring precision cancer care to every patient who needs it. By bringing together leading healthcare innovators into a unified ecosystem, we are working toward a future in which all cancer patients have access to the best personalized care, regardless of location or income. Our customers—including Intermountain Healthcare, Providence St. Joseph Health, Henry Ford Health System, Aurora Health Care, Catholic Health Initiatives and Dignity Health—manage one million active cancer cases at nearly 300 hospitals in 25 states. Headquartered in San Francisco, Syapse is backed by investors including Social Capital, Safeguard Scientifics (NYSE:SFE), Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Merck Global Health Innovation Fund, Medidata Solutions, Roche Venture Fund, and Amgen Ventures.
Contact:
Courtney Lamie
Crosscut Strategies
202-792-7200
[email protected]
